45岁及以下非肌层浸润性膀胱癌患者的肿瘤学结局:回顾性匹配队列研究
该多中心回顾性匹配队列研究比较了45岁及以下与年长非肌层浸润性膀胱癌(NMIBC)患者的肿瘤学结局。
要点
- 年轻NMIBC患者(≤45岁)肿瘤学行为与年长患者相似,但复发率更低。
核心结论
- 45岁及以下NMIBC患者的肿瘤学行为与年长患者相似,但复发率更低。
研究设计与样本
- 回顾性多中心队列研究,纳入2005-2022年加拿大4个中心诊断的≤45岁NMIBC患者158例。
- 采用倾向性评分3:1匹配,与>45岁患者350例进行比较。
- 匹配变量包括性别、原位癌、分期、分级、肿瘤大小、数量及经尿道膀胱肿瘤电切术年份。
主要发现
- 年轻组中位年龄39岁(IQR 32-42),中位随访6.0年(IQR 2.9-9.8)。
- 年轻组多数为男性(66%)、单发(78%)、低级别(64%)、Ta期(82%)肿瘤。
临床怎么用
- 年轻NMIBC患者可参考与年长患者相似的肿瘤学管理策略,但需注意其复发风险较低。
- 年长患者应加强复发监测,因复发风险显著更高。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 样本量有限(年轻组158例,匹配后124例)。
- 随访时间中位数6.0年,可能不足以评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Most bladder cancers are diagnosed as nonmuscle invasive (NMIBC), with 90% after the age of 55 years. Although the incidence of several malignancies is increasing among younger adults in whom more aggressive behavior is observed, our knowledge about NMIBC in young patients remains limited. We compared oncological outcomes in patients with NMIBC aged 45 years and younger with a cohort of older patients. MATERIALS AND METHODS: This is a retrospective study of NMIBC diagnosed at age 45 years or younger (2005-2022) from 4 Canadian centers. End points included cancer-specific mortality, risk of metastasis, progression to muscle invasion, NMIBC progression (eg, Ta/carcinoma in situ to T1), grade progression, and recurrence. Competing risk analysis and Kaplan-Meier estimates were used. Hazard ratios were calculated using Fine and Gray regression. Propensity-score matching (3:1) was used with patients older than 45 years. Scores were estimated using a logistic regression model incorporating sex, carcinoma in situ, stage, grade, tumor size, and number and year of transurethral resection of bladder tumor. RESULTS: Among 158 patients, the median age was 39 years (IQR 32-42) and median follow-up 6.0 years (IQR 2.9-9.8). The majority were male (66%), with solitary (78%), low-grade (64%), Ta (82%) tumors. After 3:1 matching, 124 younger patients were compared with 350 older patients (median age 76 years, IQR 69-82). Recurrence rates were higher in older patients (HR 1.53, 95% CI 1.09-2.14, P = .013). Cancer-specific mortality, grade progression, and progression to muscle invasion or metastasis were not significantly different (all P > .05) between groups. CONCLUSIONS: NMIBC exhibits similar behavior in patients younger than 45 years compared with older patients but with a lower recurrence rate.
引用
- St-Laurent MP, Din S, Moryousef J, et al. Oncological Outcomes of Nonmuscle-Invasive Bladder Cancer in Patients Aged 45 Years and Younger: A Retrospective Matched Cohort Study. J Urol. 2026. PMID: 42341207. doi:10.1097/JU.0000000000005183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。